RecruitingNCT07700225

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension

Sponsor

Virginia Commonwealth University

Enrollment

1,000 participants

Start Date

Sep 1, 2026

Study Type

OBSERVATIONAL

Conditions

Myotonic Dystrophy Myotonic Dystrophy 1 Myotonic Dystrophy Type 1 DM1 Myotonic Dystrophy Type 1 (DM1)Myotonic Muscular Dystrophy

Summary

Myotonic Dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder that causes progressive disability and shortened life expectancy. It is characterized by progressive weakness and myotonia, which preferentially affects the craniofacial, hand, and distal leg muscles. Many patients also experience difficulties with cognition, cardiac arrhythmias, respiratory failure, or cataracts. Currently there is no treatment to slow progression or reverse the symptoms.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with dm1, myotonic dystrophy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Virginia Commonwealth University

Richmond, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07700225

Related Trials

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

NCT0748693420 locations

Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension

NCT067478841 location